{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:56Z","timestamp":1786979936014,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00277-023-05406-z","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:02:08Z","timestamp":1694131328000},"page":"3205-3216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Salvage hematopoietic stem cell transplantation for patients with higher leukemia burden in relapsed or refractory acute myeloid leukemia: a ten-year study"],"prefix":"10.1007","volume":"102","author":[{"given":"Shan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruowen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7286-3062","authenticated-orcid":false,"given":"Linghui","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"5406_CR1","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","volume":"341","author":"B L\u00f6wenberg","year":"1999","unstructured":"L\u00f6wenberg B, Downing JR, Burnett A (1999) Acute myeloid leukemia. N Engl J Med 341:1051\u20131062. https:\/\/doi.org\/10.1056\/NEJM199909303411407","journal-title":"N Engl J Med"},{"key":"5406_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H D\u00f6hner","year":"2010","unstructured":"D\u00f6hner H, Estey EH, Amadori S et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453\u2013474. https:\/\/doi.org\/10.1182\/blood-2009-07-235358","journal-title":"Blood"},{"key":"5406_CR3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.bbmt.2014.10.025","volume":"21","author":"M Othus","year":"2015","unstructured":"Othus M, Appelbaum FR, Petersdorf SH et al (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 21:559\u2013564. https:\/\/doi.org\/10.1016\/j.bbmt.2014.10.025","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"5406_CR4","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.beha.2016.10.003","volume":"29","author":"E Estey","year":"2016","unstructured":"Estey E (2016) Why are there so few randomized trials for patients with primary refractory acute myeloid leukemia? Best Pract Res Clin Haematol 29:324\u2013328. https:\/\/doi.org\/10.1016\/j.beha.2016.10.003","journal-title":"Best Pract Res Clin Haematol"},{"key":"5406_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1182\/blood.2019001982","volume":"136","author":"S DeWolf","year":"2020","unstructured":"DeWolf S, Tallman MS (2020) How I treat relapsed or refractory AML. Blood 136:1023\u20131032. https:\/\/doi.org\/10.1182\/blood.2019001982","journal-title":"Blood"},{"key":"5406_CR6","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1182\/blood-2018-99-116964","volume":"132","author":"G Evers","year":"2018","unstructured":"Evers G, Beelen DW, Braess J et al (2018) Outcome of Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Beyond First Complete Remission (CR1). Blood 132:4649. https:\/\/doi.org\/10.1182\/blood-2018-99-116964","journal-title":"Blood"},{"key":"5406_CR7","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/cac2.12376","volume":"42","author":"C-H Yan","year":"2022","unstructured":"Yan C-H, Wang Y, Sun Y-Q et al (2022) Optimized therapeutic strategy for patients with refractory or relapsed acute myeloid leukemia: long-term clinical outcomes and health-related quality of life assessment. Cancer Commun Lond Engl 42:1387\u20131402. https:\/\/doi.org\/10.1002\/cac2.12376","journal-title":"Cancer Commun Lond Engl"},{"key":"5406_CR8","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/sj.leu.2401568","volume":"14","author":"EH Estey","year":"2000","unstructured":"Estey EH (2000) Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 14:476\u2013479. https:\/\/doi.org\/10.1038\/sj.leu.2401568","journal-title":"Leukemia"},{"key":"5406_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clml.2018.11.016","volume":"19","author":"R Ciftciler","year":"2019","unstructured":"Ciftciler R, Demiroglu H, Buyukas\u0131k Y et al (2019) Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 19:177\u2013182. https:\/\/doi.org\/10.1016\/j.clml.2018.11.016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5406_CR10","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","volume":"28","author":"M Duval","year":"2010","unstructured":"Duval M, Klein JP, He W et al (2010) Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 28:3730\u20133738. https:\/\/doi.org\/10.1200\/JCO.2010.28.8852","journal-title":"J Clin Oncol"},{"key":"5406_CR11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.bbmt.2013.01.015","volume":"19","author":"W-P Zhang","year":"2013","unstructured":"Zhang W-P, Yang D, Song X-M et al (2013) Allogeneic Peripheral Blood Stem Cell Transplantation is a Promising and Safe Choice for the Treatment of Refractory\/Relapsed Acute Myelogenous Leukemia, Even with a Higher Leukemia Burden. Biol Blood Marrow Transplant 19:653\u2013660. https:\/\/doi.org\/10.1016\/j.bbmt.2013.01.015","journal-title":"Biol Blood Marrow Transplant"},{"key":"5406_CR12","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/s41409-020-01129-1","volume":"56","author":"M Jentzsch","year":"2021","unstructured":"Jentzsch M, Grimm J, Bill M et al (2021) ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation. Bone Marrow Transplant 56:936\u2013945. https:\/\/doi.org\/10.1038\/s41409-020-01129-1","journal-title":"Bone Marrow Transplant"},{"key":"5406_CR13","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937\u2013951. https:\/\/doi.org\/10.1182\/blood-2009-03-209262","journal-title":"Blood"},{"key":"5406_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"5406_CR15","doi-asserted-by":"publisher","first-page":"1017850","DOI":"10.3389\/fimmu.2022.1017850","volume":"13","author":"Z Huang","year":"2022","unstructured":"Huang Z, Yan H, Teng Y et al (2022) Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia. Front Immunol 13:1017850. https:\/\/doi.org\/10.3389\/fimmu.2022.1017850","journal-title":"Front Immunol"},{"key":"5406_CR16","first-page":"663","volume":"10","author":"R Reshef","year":"2012","unstructured":"Reshef R (2012) Prevention of graft-versus-host disease. Clin Adv Hematol Oncol HO 10:663\u2013665","journal-title":"Clin Adv Hematol Oncol HO"},{"key":"5406_CR17","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1016\/j.scib.2021.06.002","volume":"66","author":"Y Wang","year":"2021","unstructured":"Wang Y, Liu Q-F, Lin R et al (2021) Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial. Sci Bull 66:2498\u20132505. https:\/\/doi.org\/10.1016\/j.scib.2021.06.002","journal-title":"Sci Bull"},{"key":"5406_CR18","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJM197504242921706","volume":"292","author":"ED Thomas","year":"1975","unstructured":"Thomas ED, Storb R, Clift RA et al (1975) Bone-marrow transplantation (second of two parts). N Engl J Med 292:895\u2013902. https:\/\/doi.org\/10.1056\/NEJM197504242921706","journal-title":"N Engl J Med"},{"key":"5406_CR19","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S et al (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 11:945\u2013956. https:\/\/doi.org\/10.1016\/j.bbmt.2005.09.004","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"5406_CR20","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1200\/JCO.2013.50.5768","volume":"32","author":"M Stelljes","year":"2014","unstructured":"Stelljes M, Krug U, Beelen DW et al (2014) Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol Off J Am Soc Clin Oncol 32:288\u2013296. https:\/\/doi.org\/10.1200\/JCO.2013.50.5768","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5406_CR21","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","volume":"363","author":"TA Gooley","year":"2010","unstructured":"Gooley TA, Chien JW, Pergam SA et al (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363:2091\u20132101. https:\/\/doi.org\/10.1056\/NEJMoa1004383","journal-title":"N Engl J Med"},{"key":"5406_CR22","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1200\/JCO.2010.32.5001","volume":"29","author":"JT Horan","year":"2011","unstructured":"Horan JT, Logan BR, Agovi-Johnson M-A et al (2011) Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol Off J Am Soc Clin Oncol 29:805\u2013813. https:\/\/doi.org\/10.1200\/JCO.2010.32.5001","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5406_CR23","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.3109\/10428194.2012.741230","volume":"54","author":"R Devillier","year":"2013","unstructured":"Devillier R, Crocchiolo R, Etienne A et al (2013) Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia. Leuk Lymphoma 54:1228\u20131234. https:\/\/doi.org\/10.3109\/10428194.2012.741230","journal-title":"Leuk Lymphoma"},{"key":"5406_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.bbmt.2012.07.021","volume":"19","author":"M Liga","year":"2013","unstructured":"Liga M, Triantafyllou E, Tiniakou M et al (2013) High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 19:75\u201381. https:\/\/doi.org\/10.1016\/j.bbmt.2012.07.021","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"5406_CR25","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/bmt.2015.234","volume":"51","author":"Z Jedlickova","year":"2016","unstructured":"Jedlickova Z, Schmid C, Koenecke C et al (2016) Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation. Bone Marrow Transplant 51:663\u2013667. https:\/\/doi.org\/10.1038\/bmt.2015.234","journal-title":"Bone Marrow Transplant"},{"key":"5406_CR26","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood-2018-99-111582","volume":"132","author":"B Oran","year":"2018","unstructured":"Oran B, de Lima M, Garcia-Manero G et al (2018) Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. Blood 132:971. https:\/\/doi.org\/10.1182\/blood-2018-99-111582","journal-title":"Blood"},{"key":"5406_CR27","doi-asserted-by":"crossref","unstructured":"(2018) Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol 19:1668\u20131679. 10.1016\/S1470-2045(18)30580-1","DOI":"10.1016\/S1470-2045(18)30580-1"},{"key":"5406_CR28","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","volume":"38","author":"A Burchert","year":"2020","unstructured":"Burchert A, Bug G, Fritz LV et al (2020) Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol Off J Am Soc Clin Oncol 38:2993\u20133002. https:\/\/doi.org\/10.1200\/JCO.19.03345","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5406_CR29","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1182\/blood.2021011583","volume":"139","author":"AE Perl","year":"2022","unstructured":"Perl AE, Larson RA, Podoltsev NA et al (2022) Follow-up of patients with R\/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood 139:3366\u20133375. https:\/\/doi.org\/10.1182\/blood.2021011583","journal-title":"Blood"},{"key":"5406_CR30","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/ejh.13692","volume":"107","author":"JD Griffin","year":"2021","unstructured":"Griffin JD, Song Y, Yang H et al (2021) Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: Real-world treatment patterns and outcomes. Eur J Haematol 107:553\u2013565. https:\/\/doi.org\/10.1111\/ejh.13692","journal-title":"Eur J Haematol"},{"key":"5406_CR31","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/leu.2014.145","volume":"28","author":"M Stern","year":"2014","unstructured":"Stern M, de Wreede LC, Brand R et al (2014) Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. Leukemia 28:2235\u20132240. https:\/\/doi.org\/10.1038\/leu.2014.145","journal-title":"Leukemia"},{"key":"5406_CR32","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1182\/blood.V118.21.1938.1938","volume":"118","author":"D Schneidawind","year":"2011","unstructured":"Schneidawind D, Federmann B, Faul C et al (2011) Allogeneic Hematopoietic Cell Transplantation with FLAMSA-RIC Can Overcome the Poor Prognosis of Primary Refractory or Relapsed AML. Blood 118:1938. https:\/\/doi.org\/10.1182\/blood.V118.21.1938.1938","journal-title":"Blood"},{"key":"5406_CR33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.20.02529","volume":"39","author":"C Peters","year":"2021","unstructured":"Peters C, Dalle J-H, Locatelli F et al (2021) Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. J Clin Oncol Off J Am Soc Clin Oncol 39:295\u2013307. https:\/\/doi.org\/10.1200\/JCO.20.02529","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5406_CR34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev.immunol.25.022106.141606","volume":"25","author":"LA Welniak","year":"2007","unstructured":"Welniak LA, Blazar BR, Murphy WJ (2007) Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 25:139\u2013170. https:\/\/doi.org\/10.1146\/annurev.immunol.25.022106.141606","journal-title":"Annu Rev Immunol"},{"key":"5406_CR35","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1182\/blood-2011-04-347229","volume":"118","author":"RL Bakst","year":"2011","unstructured":"Bakst RL, Tallman MS, Douer D, Yahalom J (2011) How I treat extramedullary acute myeloid leukemia. Blood 118:3785\u20133793. https:\/\/doi.org\/10.1182\/blood-2011-04-347229","journal-title":"Blood"},{"key":"5406_CR36","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2021.030","volume":"13","author":"L Fianchi","year":"2021","unstructured":"Fianchi L, Quattrone M, Criscuolo M et al (2021) Extramedullary Involvement in Acute Myeloid Leukemia. A Single Center Ten Years\u2019 Experience. Mediterr J Hematol. Infect Dis 13:e2021030. https:\/\/doi.org\/10.4084\/MJHID.2021.030","journal-title":"Infect Dis"},{"key":"5406_CR37","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/bmt.2015.82","volume":"50","author":"SD Goyal","year":"2015","unstructured":"Goyal SD, Zhang M-J, Wang H-L et al (2015) Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. Bone Marrow Transplant 50:1057\u20131062. https:\/\/doi.org\/10.1038\/bmt.2015.82","journal-title":"Bone Marrow Transplant"},{"key":"5406_CR38","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1007\/s00277-020-04283-0","volume":"99","author":"Y Lu","year":"2020","unstructured":"Lu Y, Zhao Y-L, Zhang J-P et al (2020) Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory\/relapsed acute myeloid leukemia not in remission status. Ann Hematol 99:2911\u20132925. https:\/\/doi.org\/10.1007\/s00277-020-04283-0","journal-title":"Ann Hematol"},{"key":"5406_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.canlet.2018.08.030","volume":"438","author":"Y Wang","year":"2018","unstructured":"Wang Y, Chen H, Chen J et al (2018) The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. Cancer Lett 438:63\u201375. https:\/\/doi.org\/10.1016\/j.canlet.2018.08.030","journal-title":"Cancer Lett"},{"key":"5406_CR40","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1007\/s11427-019-1610-2","volume":"63","author":"Y Wang","year":"2020","unstructured":"Wang Y, Liu Q-F, Wu D-P et al (2020) Impact of prophylactic\/preemptive donor lymphocyte infusion and intensified conditioning for relapsed\/refractory leukemia: a real-world study. Sci China Life Sci 63:1552\u20131564. https:\/\/doi.org\/10.1007\/s11427-019-1610-2","journal-title":"Sci China Life Sci"},{"key":"5406_CR41","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/s41423-020-00597-1","volume":"18","author":"H Guo","year":"2021","unstructured":"Guo H, Chang Y-J, Hong Y et al (2021) Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cell Mol Immunol 18:1172\u20131185. https:\/\/doi.org\/10.1038\/s41423-020-00597-1","journal-title":"Cell Mol Immunol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05406-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05406-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05406-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T17:03:43Z","timestamp":1697043823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05406-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["5406"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05406-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]},"assertion":[{"value":"15 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Ethical Committee of Wuhan Union Hospital in China approved this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}